Aardvark (aard) Investors Contact Hagens Berman - Aug 28

The Story

Hagens Berman Sobol Shapiro LLP has notified investors in Aardvark Therapeutics, Inc., NASDAQ: AARD, that a securities class action has been filed, and it set a lead plaintiff deadline of October 13, 2026. The firm says investors who purchased or acquired Aardvark common stock may be affected and should contact Hagens Berman.

Why It Matters For Your Portfolio

• Lead plaintiff deadline is October 13, 2026, which is a firm date investors must note if they want to participate in the case or seek leadership roles in litigation.
• The notice was issued on Aug. 28, 2026, signaling an immediate legal development that can create headline risk for $AARD and may affect trading volatility.
• The filing targets investors who purchased or acquired Aardvark common stock, meaning shareholder positions could be directly implicated; the notice did not include share-price or revenue figures in the release.
• Legal proceedings can result in direct costs, settlements, or reputational impact, all of which are material risks for holders of $AARD to monitor.

The Trade

This matters most for current shareholders and short-term traders who need to monitor legal and market reactions, and for larger holders considering position sizing. Watch for court filings, any Hagens Berman updates, analyst commentary, and changes in $AARD trading volume up to and after the October 13, 2026 lead plaintiff deadline. This note is informational only and not investment advice.